203 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
16 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
74
Ending by 2030
Dec 2026
Next term end
69
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2030 · High confidence
Also notable
Ends Aug 2030 · High confidence
Also notable
Ends Aug 2029 · High confidence
Also notable
Ends Oct 2028 · High confidence
Also notable
Ends Mar 2027 · High confidence
Also notable
Ends May 2028 · High confidence
Also notable
Ends Jan 2031 · High confidence
Also notable
Ends Aug 2029 · High confidence
Dry powder drug delivery system
US 8,485,180
Cited by 173 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Dry Powder Inhaler and System for Drug Delivery
US 10,201,672
Cited by 54 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2030.
A Method of Treating Diabetes Type 2 by Metformin and an Ultrarapid Acting Insulin
US 8,119,593
Cited by 107 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Catalysis of Diketopiperazine Synthesis
US 7,709,639
Cited by 126 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Multi-Cartridge Fluid Delivery Device
US 7,914,499
Cited by 131 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent
US 8,039,431
Cited by 149 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents
US 8,314,106
Cited by 140 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
A Method of Controlling Glycemia by Ultrarapid Acting Insulin Without Adjusting an Insulin Dose for Meal Content
US 8,258,095
Cited by 81 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 26 to 30, 2026 · next Nov 26
- 3 fees due Dec 4 to 6, 2026 · next Dec 4
- 3 fees due Jan 7 to 23, 2027 · next Jan 7
- 5 fees due Feb 8 to 22, 2027 · next Feb 8
- 2 fees due Mar 17 to 24, 2027 · next Mar 17
- 2 fees due Apr 24, 2027
- 3 fees due May 17 to 24, 2027 · next May 17
- 4 fees due Jun 10 to 29, 2027 · next Jun 10
- 1 fee due Jul 12, 2027The maintenance fee for Methods and Compositions for Treating Pain (US 9,233,159) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Mouthpiece Cover for an Inhaler (US 10,561,806) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 4 fees due Sep 3 to 30, 2027 · next Sep 3
- 2 fees due Oct 9 to 21, 2027 · next Oct 9
- 3 fees due Nov 5 to 17, 2027 · next Nov 5
Recent changes
- Oct 28Assignment recorded on 1 record: Richardson, Peter and 4 others to MannKind Corporation Recorded Oct 28, 2026, executed Sep 16, 2009. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76546, frame 389.
- Oct 12Assignment recorded on 1 record: Smutney, Chad C. and 7 others to MannKind Corporation Recorded Oct 12, 2026, executed Jun 4, 2009. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76341, frame 891.
- 2 of the patents on this record were granted since Aug 22, 2026
- 16 terms have ended since Aug 22, 2026
- Nov 20 US 8,230,887 Powder Dispensing and Sensing Apparatus and Methods · term ended
- Nov 20 US 8,220,505 Powder Transport Systems and Methods · term ended
- Nov 9 US 8,166,970 Inhalation Apparatus · term ended
- Sep 25 US D667,946 Fluid Transfer Device · term ended
- Sep 14 US 9,717,689 Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents · term ended
- Sep 14 US 9,446,001 Increasing Drug Affinity for Crystalline Microparticle Surfaces · term ended
- Sep 14 US 9,283,193 Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents · term ended
- Sep 14 US 9,089,497 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces · term ended
- Sep 14 US 9,066,881 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces · term ended
- Sep 14 US 7,803,404 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces · term ended
- Sep 14 US 7,799,344 Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents · term ended
- Sep 14 US 11,103,459 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces · term ended
- Sep 14 US 11,013,692 Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents · term ended
- Sep 14 US 10,357,459 Method of Drug Formulation Based on Increasing the Affinity of Crystalline Microparticle Surfaces for Active Agents · term ended
- Sep 14 US 10,143,655 Method of Drug Formulation · term ended
What they patent
The largest of its 69 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D671,842 | Blister Packaging In force · High confidence | In force | High confidence | |
| US D674,893 | Inhaler Device In force · High confidence | In force | High confidence | |
| US 8,512,932 | Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent In force · High confidence | In force | High confidence | |
| US 9,241,903 | Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent In force · High confidence | In force | High confidence | |
| US 10,130,581 | Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent In force · High confidence | In force | High confidence | |
| US 10,376,466 | Method for Improving the Pharmaceutic Properties of Microparticles Comprising Diketopiperazine and an Active Agent In force · High confidence | In force | High confidence | |
| US 7,914,499 | Multi-Cartridge Fluid Delivery Device In force · High confidence | In force | High confidence | |
| US 8,361,053 | Multi-Cartridge Fluid Delivery Device In force · High confidence | In force | High confidence | |
| US 10,493,199 | Multi-Cartridge Fluid Delivery Device In force · High confidence | In force | High confidence | |
| US 8,420,604 | Method of Drug Formulation of Compositions Comprising Crystalline Microparticle Surfaces In force · High confidence | In force | High confidence |
Also on record, not counted in the 203: 2 patents in force now held by others · 131 patents ended · 66 applications pending · 78 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.